Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.

Zhang F, Tong Y, Su N, Li Y, Tang L, Huang L, Tong N

Journal of diabetes10 Sept 2014Cited by 47 (Europe PMC)

PMID25043423DOI10.1111/1753-0407.12198PepBankPUB-25043423

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In obese or overweight adults without diabetes, the meta-analysis suggests that liraglutide may reduce weight in a dose-dependent fashion.
In plain wordsIn overweight adults without diabetes, liraglutide may cause more weight loss at higher doses, according to this review.
Peptide
Liraglutide
Outcome
DecreaseWeight loss dose-dependence of liraglutide
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
and liraglutide may work in a dose-dependent fashion.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed.
Summary · context
A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks.
Report a problemFND-2504342302

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese or overweight adults without diabetes, pooled GLP-1 receptor agonists produced a larger weight loss than control groups (weighted mean difference -2.85 kg).
In plain wordsIn overweight adults without diabetes, GLP-1 drugs as a group led to more weight loss than control groups.
Peptide
Liraglutide
Outcome
DecreaseWeight loss versus control
Study
n = 1,345
Comparator
Control groups
Outcome group
Body weight · Metabolic and weight
Measurements
Weighted mean difference, weight
−2.85 kg
GLP-1RA vs control
Source sentences
Summary
Participants in GLP-1RA groups achieved a larger weight loss than those in control groups (-2.85 kg, 95%CI -3.55 to -2.14)
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed.
Summary · context
A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2504342301
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese or overweight adults without diabetes, pooled GLP-1 receptor agonists reduced body mass index.
In plain wordsIn overweight adults without diabetes, GLP-1 drugs as a group lowered body mass index.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1RAs also reduced body mass index (BMI)
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed.
Summary · context
A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2504342303
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese or overweight adults without diabetes, pooled GLP-1 receptor agonists reduced waist circumference.
In plain wordsIn overweight adults without diabetes, GLP-1 drugs as a group reduced waist size.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1RAs also reduced body mass index (BMI) and waist circumferences (WC) and benefited systolic blood pressure and triglyceride regulation.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed.
Summary · context
A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2504342304
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese or overweight adults without diabetes, pooled GLP-1 receptor agonists benefited systolic blood pressure.
In plain wordsIn overweight adults without diabetes, GLP-1 drugs as a group improved systolic blood pressure.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
GLP-1RAs also reduced body mass index (BMI) and waist circumferences (WC) and benefited systolic blood pressure and triglyceride regulation.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed.
Summary · context
A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2504342305
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese or overweight adults without diabetes, pooled GLP-1 receptor agonists benefited triglyceride regulation.
In plain wordsIn overweight adults without diabetes, GLP-1 drugs as a group improved triglyceride levels.
Peptide
Liraglutide
Outcome
DecreaseTriglyceride regulation
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
GLP-1RAs also reduced body mass index (BMI) and waist circumferences (WC) and benefited systolic blood pressure and triglyceride regulation.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed.
Summary · context
A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2504342306
07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In obese or overweight adults without diabetes, pooled GLP-1 receptor agonists were associated with more nausea and vomiting events.
In plain wordsIn overweight adults without diabetes, GLP-1 drugs as a group were linked to more nausea and vomiting.
Peptide
Liraglutide
Outcome
IncreaseNausea and vomiting events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
But GLP-1RAs were associated with increased nausea and vomiting events.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed.
Summary · context
A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2504342307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.